Larimar Therapeutics (LRMR) Income from Continuing Operations (2013 - 2025)
Larimar Therapeutics (LRMR) posted Income from Continuing Operations of 65518000.0 for Q4 2025, down 29.26% on a QoQ basis from 50687000.0 in Q3 2025, and up 67.93% year-over-year from 39014185.19 in Q4 2024.
Larimar Therapeutics (LRMR) Income from Continuing Operations (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 65518000.0 for Q4 2025.
- Quarterly Income from Continuing Operations rose 67.93% year-over-year to 65518000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 182420000.0 (up 37.55% YoY) and the FY2025 annual result came in at 173997000.0, up 34.07% from the prior year.
- Income from Continuing Operations was 65518000.0 for Q4 2025 at Larimar Therapeutics, down from 50687000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9697000.0 in Q1 2023 and bottomed at 204321000.0 in Q4 2024.
- A 5-year average of 52580800.0 and a median of 26699000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 186.01% — and 2025, when it soared 67.93%.
- Larimar Therapeutics' Income from Continuing Operations stood at 133102000.0 in 2021, then decreased by 6.14% to 141270000.0 in 2022, then retreated by 10.38% to 155932000.0 in 2023, then sank by 31.03% to 204321000.0 in 2024, then surged by 67.93% to 65518000.0 in 2025.
- Business Quant data shows LRMR's Income from Continuing Operations at 65518000.0 in Q4 2025, 50687000.0 in Q3 2025, and 28980000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Larimar Therapeutics | 36.57 Mn | -100.28 Mn | - | -65.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -65.52 Mn |
| Sep 30, 2025 | -50.69 Mn |
| Jun 30, 2025 | -28.98 Mn |
| Mar 31, 2025 | -37.24 Mn |
| Dec 31, 2024 | -204.32 Mn |
| Sep 30, 2024 | -25.66 Mn |
| Jun 30, 2024 | -34.40 Mn |
| Mar 31, 2024 | -27.73 Mn |
| Dec 31, 2023 | -155.93 Mn |
| Sep 30, 2023 | -17.60 Mn |
| Jun 30, 2023 | -16.62 Mn |
| Mar 31, 2023 | -9.70 Mn |
| Dec 31, 2022 | -141.27 Mn |
| Sep 30, 2022 | -10.86 Mn |
| Jun 30, 2022 | -11.18 Mn |
| Mar 31, 2022 | -17.39 Mn |
| Dec 31, 2021 | -133.10 Mn |
| Sep 30, 2021 | -19.69 Mn |
| Jun 30, 2021 | -21.94 Mn |
| Mar 31, 2021 | -21.80 Mn |